Advancing Hepatitis Elimination: HBV, HDV, and HCV

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 418

Special Issue Editor


E-Mail Website
Guest Editor
Microbiology Department, University Hospital San Cecilio, Granada, Spain
Interests: clinical virology; molecular epidemiology and resistance of HIV and hepatitis; sexually transmitted infections; Mycoplasma genitalium epidemiologya, pathogenesis and resistance to antibiotics; microbiome and metagenome analysis; infectious and non infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The global elimination of viral hepatitis remains a critical public health goal, with hepatitis B virus (HBV), hepatitis D virus (HDV), and hepatitis C virus (HCV) representing significant challenges to healthcare systems worldwide. Despite advancements in diagnostics, antiviral therapies, and vaccination programs, substantial gaps remain in achieving the World Health Organization's elimination targets by 2030.

This Special Issue invites cutting-edge research, reviews, and perspectives focusing on innovative strategies, barriers, and opportunities in the fight against HBV, HDV, and HCV. Topics of interest include but are not limited to novel diagnostic tools, therapeutic approaches, vaccination strategies, epidemiological insights, and public health policies aimed at prevention and elimination.

By bringing together a diverse collection of studies, we aim to foster collaboration across disciplines and provide actionable insights that can accelerate the elimination of these debilitating infections. We welcome contributions from clinicians, researchers, and public health experts to shed light on the current state of hepatitis elimination and the road ahead.

Dr. Federico Garcia
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatitis elimination
  • HBV
  • HCV
  • HDV

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 738 KiB  
Article
Comprehensive Diagnosis of Viral Hepatitis in Spain: Bases for Implementation
by Joaquin Cabezas, Antonio Aguilera, Federico García, Raquel Domínguez-Hernández, Araceli Casado-Gómez, Nataly Espinoza-Cámac, Miguel Ángel Casado and Javier Crespo
Viruses 2025, 17(5), 667; https://doi.org/10.3390/v17050667 - 3 May 2025
Viewed by 225
Abstract
In 2022, scientific societies agreed on a document with recommendations for a comprehensive diagnosis of viral hepatitis (B, C, and D). The aim was to evaluate the situation in Spain regarding the comprehensive diagnosis of viral hepatitis in a single blood draw before [...] Read more.
In 2022, scientific societies agreed on a document with recommendations for a comprehensive diagnosis of viral hepatitis (B, C, and D). The aim was to evaluate the situation in Spain regarding the comprehensive diagnosis of viral hepatitis in a single blood draw before it is recommended. A panel of experts prepared a structured survey directed at hospitals (public or private with teaching accreditation) with ≥200 beds (sent 20 October 2022, closed 1 December 2022). The response rate was 61% (79/129; 52 hospitals with >500 beds). Among the participating hospitals, all could perform tests for HBsAg, anti-HCV, and HIV serology; 94% could perform PCR testing for HCV, 63% could test for anti-HDV, and 28% could test for HDV-RNA (67% [53/79] outsourced this testing). Point-of-care (POC) testing availability was low (24%), with 84% of these tests being supervised by the reference microbiological laboratory and the results being registered in the patients’ medical history. Ninety percent of the centers carried out the diagnosis in a single step (99% HCV, 70% HBV, 48% HDV, and 44% HBV-HDV). In addition, 77% used some communication strategy when an active infection was encountered (100% HCV, 49% HBV, and 31% HDV). Only 20% had an automated system for scheduling a specialist physician appointment. Most hospitals had the means for a comprehensive diagnosis of viral hepatitis in a single sample, but <50% could test for HBV/HDV. Alerts for continuity of care were available for HCV, but not HBV or HDV. POC device implementation is important for decentralized testing. Full article
(This article belongs to the Special Issue Advancing Hepatitis Elimination: HBV, HDV, and HCV)
Show Figures

Figure 1

Back to TopTop